DGAP-News: Aladdin Healthcare Technologies achieves OTCQX listing in the USA

Aladdin Healthcare Technologies achieves OTCQX listing in the USA

- Aladdin shares enter world's largest technology market
- US listing makes Aladdin more appealing for international investors
- More availability and better profile of Aladdin shares through OTCQX listing

BERLIN/LONDON, August 31, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has applied and qualified to trade on the OTCQX market maintaining its listing on the Düsseldorf and the Frankfurt Stock Exchange. This listing will enhance the availability and profile of Aladdin shares to the international investing community.

OTCQX, operated by the OTC Markets Group, is the top tier of the three OTC marketplaces offered. OTCQX companies must meet high financial standards, practice good corporate governance and demonstrate compliance with applicable securities laws. OTCQX listing of Aladdin shares will increase the attractiveness and accessibility of the shares to the capital markets and facilitate greater attention from investors within the world's largest technology market, the USA.

"With our inclusion in the US stock market, we are now moving into the world's best capital market for healthcare technology taking a decisive step to accompany our rapidly growing business. As a leading developer of AI healthcare diagnostics and drug discovery applications for age-related diseases, we see it as a great opportunity to present our business model and its growth prospects to investors who are attracted to innovative companies with rapid growth potential," said Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE.

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information:

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: [email protected]

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330
Email: [email protected]
www.crossalliance.de